Sugi Predict

Sugi Predict / Compounds / SCHEMBL598349

SCHEMBL598349

SCHEMBL598349

CC(C)(C)C(=O)N1C(=O)CC[C@H]1Cc1ccc(-c2ccccc2)cc1

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ HCRTR1 O43613 1/20 0.39
▸ HCRTR2 O43614 1/20 0.39
▸ MME P08473 1/20 0.39
▸ ACE P12821 1/20 0.39
▸ ACE2 Q9BYF1 1/20 0.39
▸ CYP26A1 O43174 1/20 0.39
▸ RIPK1 Q13546 2/20 0.37
▸ SMN1; SMN2 Q16637 2/20 0.37
▸ RAB9A P51151 1/20 0.37
▸ FFAR1 O14842 1/20 0.37
▸ CCR5 P51681 1/20 0.37
▸ ABHD6 Q9BV23 3/20 0.36
▸ DAGLA Q9Y4D2 3/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ TSHR P16473 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL598350 1.00 HCRTR1 (0.39) HCRTR1HCRTR2MMEACEACE2
SCHEMBL14900527 0.88 GRM2 (0.43) MMERIPK1
SCHEMBL8193733 0.86 RIPK1 (0.36) MMEACEACE2CYP26A1RIPK1
SCHEMBL8181740 0.86 HCRTR1 (0.38) HCRTR1HCRTR2CYP26A1SMN1; SMN2RAB9A
SCHEMBL598931 0.86 BRD4 (0.42) HCRTR1HCRTR2CYP26A1SMN1; SMN2RAB9A
SCHEMBL598932 0.86 BRD4 (0.42) HCRTR1HCRTR2CYP26A1SMN1; SMN2RAB9A
SCHEMBL3395452 0.85 CYP26A1 (0.42) HCRTR1HCRTR2CYP26A1SMN1; SMN2RAB9A
SCHEMBL3395450 0.85 CYP26A1 (0.42) HCRTR1HCRTR2CYP26A1SMN1; SMN2RAB9A
SCHEMBL9963912 0.85 ALDH1A1 (0.35) SMN1; SMN2RAB9ACCR5MEN1ALDH1A1
SCHEMBL598705 0.84 KLK7 (0.45) HCRTR1HCRTR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11851443-B2 Neprilysin inhibitors THERAVANCE BIOPHARMA R&D IP, LLC (US) 2023-12-26 — — US disclosed
US-20220298173-A1 NEPRILYSIN INHIBITORS THERAVANCE BIOPHARMA R&D IP, LLC (US) 2022-09-22 — — US disclosed
US-11261197-B2 Neprilysin inhibitors THERAVANCE BIOPHARMA R&D IP, LLC (US) 2022-03-01 — — US disclosed
US-20210079017-A1 NEPRILYSIN INHIBITORS THERAVANCE BIOPHARMA R&D IP, LLC (US) 2021-03-18 — — US disclosed
US-20210079017-A1 NEPRILYSIN INHIBITORS THERAVANCE BIOPHARMA R&D IP, LLC (US) 2021-03-18 — — US disclosed
US-10759813-B2 Neprilysin inhibitors THERAVANCE BIOPHARMA R&D IP, LLC (US) 2020-09-01 — — US disclosed
US-10759813-B2 Neprilysin inhibitors THERAVANCE BIOPHARMA R&D IP, LLC (US) 2020-09-01 — — US disclosed
US-20200031847-A1 NEPRILYSIN INHIBITORS THERAVANCE BIOPHARMA R&D IP, LLC (US) 2020-01-30 — — US disclosed
US-20200031847-A1 NEPRILYSIN INHIBITORS THERAVANCE BIOPHARMA R&D IP, LLC (US) 2020-01-30 — — US disclosed
US-10336773-B2 Neprilysin inhibitors THERAVANCE BIOPHARMA R&D IP, LLC (US) 2019-07-02 — — US disclosed
CN-101952249-A Process and intermediates for the preparation of 5-biphenyl-4-yl-2-methylpentanoic acid derivatives NOVARTIS AG 2011-01-19 — — CN disclosed
EP-2245009-A2 PROCESS AND INTERMEDIATES FOR THE PREPARATION OF 5-BIPHENYL-4-YL-2-METHYLPENTANOIC ACID DERIVATIVES Novartis AG (CH) 2010-11-03 — — EP disclosed
US-20100113801-A1 Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid NOVARTIS PHARMACEUTICALS CORPORATION 2010-05-06 — — US disclosed
US-20100113801-A1 Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid NOVARTIS PHARMACEUTICALS CORPORATION 2010-05-06 — — US disclosed
US-20100113801-A1 Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid NOVARTIS PHARMACEUTICALS CORPORATION 2010-05-06 — — US disclosed
EP-2121578-A2 NEW PROCESS Novartis AG (CH) 2009-11-25 — — EP disclosed
WO-2009090251-A2 NEW PROCESSES NOVARTIS AG (CH) 2009-07-23 — — WO disclosed
WO-2009090251-A2 NEW PROCESSES NOVARTIS AG (CH) 2009-07-23 — — WO disclosed
WO-2008083967-A2 PROCESS FOR PREPARING 5-BIPHENYL-4-AMINO-2-METHYL PENTANOIC ACID NOVARTIS AG (CH) 2008-07-17 — — WO disclosed
WO-2008083967-A2 PROCESS FOR PREPARING 5-BIPHENYL-4-AMINO-2-METHYL PENTANOIC ACID NOVARTIS AG (CH) 2008-07-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10759813-B2 Neprilysin inhibitors MME, REN, ACE HCRTR1 191/4885HCRTR2 469/4885MME 1/4885
US-20100113801-A1 Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid MME, REN, PAH HCRTR1 2568/4885HCRTR2 2878/4885MME 1/4885
US-11261197-B2 Neprilysin inhibitors MME, REN, ACE HCRTR1 191/4885HCRTR2 469/4885MME 1/4885
US-10336773-B2 Neprilysin inhibitors MME, REN, ACE HCRTR1 191/4885HCRTR2 469/4885MME 1/4885
US-20210079017-A1 NEPRILYSIN INHIBITORS MME, REN, ACE HCRTR1 191/4885HCRTR2 469/4885MME 1/4885
US-20200031847-A1 NEPRILYSIN INHIBITORS MME, REN, ACE HCRTR1 191/4885HCRTR2 469/4885MME 1/4885
US-20220298173-A1 NEPRILYSIN INHIBITORS MME, REN, ACE HCRTR1 191/4885HCRTR2 473/4885MME 1/4885
US-11851443-B2 Neprilysin inhibitors MME, REN, ACE HCRTR1 191/4885HCRTR2 469/4885MME 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.